Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Luis M. A. Oliveira, Thomas Gasser, Robert Edwards, Markus Zweckstetter, Ronald Melki, Leonidas Stefanis, Hilal A. Lashuel, David Sulzer, Kostas Vekrellis, Glenda M. Halliday, Julianna J. Tomlinson, Michael Schlossmacher, Poul Henning Jensen, Julia Schulze-Hentrich, Olaf Riess, Warren D. Hirst, Omar El-Agnaf, Brit Mollenhauer, Peter Lansbury, Tiago F. Outeiro

Open source

DOI: 10.1038/s41531-021-00203-9
Published: 2021-07-26
Container: npj Parkinson's Disease
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41531-021-00203-9,
  title = {Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease},
  author = {Luis M. A. Oliveira and Thomas Gasser and Robert Edwards and Markus Zweckstetter and Ronald Melki and Leonidas Stefanis and Hilal A. Lashuel and David Sulzer and Kostas Vekrellis and Glenda M. Halliday and Julianna J. Tomlinson and Michael Schlossmacher and Poul Henning Jensen and Julia Schulze-Hentrich and Olaf Riess and Warren D. Hirst and Omar El-Agnaf and Brit Mollenhauer and Peter Lansbury and Tiago F. Outeiro},
  year = {2021},
  journal = {npj Parkinson's Disease},
  doi = {10.1038/s41531-021-00203-9},
  url = {https://doi.org/10.1038/s41531-021-00203-9}
}

RIS

TY  - JOUR
TI  - Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
AU  - Luis M. A. Oliveira
AU  - Thomas Gasser
AU  - Robert Edwards
AU  - Markus Zweckstetter
AU  - Ronald Melki
AU  - Leonidas Stefanis
AU  - Hilal A. Lashuel
AU  - David Sulzer
AU  - Kostas Vekrellis
AU  - Glenda M. Halliday
AU  - Julianna J. Tomlinson
AU  - Michael Schlossmacher
AU  - Poul Henning Jensen
AU  - Julia Schulze-Hentrich
AU  - Olaf Riess
AU  - Warren D. Hirst
AU  - Omar El-Agnaf
AU  - Brit Mollenhauer
AU  - Peter Lansbury
AU  - Tiago F. Outeiro
PY  - 2021
JO  - npj Parkinson's Disease
DO  - 10.1038/s41531-021-00203-9
UR  - https://doi.org/10.1038/s41531-021-00203-9
ER  -

APA

Oliveira, L. M. A., Gasser, T., Edwards, R., Zweckstetter, M., Melki, R., Stefanis, L., Lashuel, H. A., Sulzer, D., Vekrellis, K., Halliday, G. M., Tomlinson, J. J., Schlossmacher, M., Jensen, P. H., Schulze-Hentrich, J., Riess, O., Hirst, W. D., El-Agnaf, O., Mollenhauer, B., Lansbury, P., & Outeiro, T. F. (2021). Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. npj Parkinson's Disease. https://doi.org/10.1038/s41531-021-00203-9

Source records

crossref · retrieved 2026-09-26T02:45:12.494Z